REGENERON PHARMACEUTICALS (1REGN.MI) Stock Fundamental Analysis
BIT:1REGN - Euronext Milan - US75886F1075 - Common Stock - Currency: EUR
Taking everything into account, 1REGN scores 7 out of 10 in our fundamental rating. 1REGN was compared to 72 industry peers in the Biotechnology industry. 1REGN gets an excellent profitability rating and is at the same time showing great financial health properties. A decent growth rate in combination with a cheap valuation! Better keep an eye on 1REGN. These ratings would make 1REGN suitable for value and quality investing!
1. Profitability
1.1 Basic Checks
1REGN had positive earnings in the past year.
In the past year 1REGN had a positive cash flow from operations.
In the past 5 years 1REGN has always been profitable.
In the past 5 years 1REGN always reported a positive cash flow from operatings.
1.2 Ratios
1REGN has a better Return On Assets (11.69%) than 91.67% of its industry peers.
1REGN has a better Return On Equity (15.03%) than 83.33% of its industry peers.
With an excellent Return On Invested Capital value of 9.36%, 1REGN belongs to the best of the industry, outperforming 84.72% of the companies in the same industry.
1REGN had an Average Return On Invested Capital over the past 3 years of 11.56%. This is below the industry average of 13.59%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.69% | ||
| ROE | 15.03% | ||
| ROIC | 9.36% |
ROA(3y)12.83%
ROA(5y)18.14%
ROE(3y)16.47%
ROE(5y)24.86%
ROIC(3y)11.56%
ROIC(5y)16.89%
1.3 Margins
Looking at the Profit Margin, with a value of 31.07%, 1REGN belongs to the top of the industry, outperforming 93.06% of the companies in the same industry.
1REGN's Profit Margin has improved in the last couple of years.
With an excellent Operating Margin value of 29.70%, 1REGN belongs to the best of the industry, outperforming 90.28% of the companies in the same industry.
In the last couple of years the Operating Margin of 1REGN has remained more or less at the same level.
The Gross Margin of 1REGN (87.01%) is better than 84.72% of its industry peers.
1REGN's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 29.7% | ||
| PM (TTM) | 31.07% | ||
| GM | 87.01% |
OM growth 3Y-18.89%
OM growth 5Y1.11%
PM growth 3Y-14.8%
PM growth 5Y2.92%
GM growth 3Y0.85%
GM growth 5Y-0.68%
2. Health
2.1 Basic Checks
1REGN has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
1REGN has about the same amout of shares outstanding than it did 1 year ago.
1REGN has less shares outstanding than it did 5 years ago.
1REGN has a better debt/assets ratio than last year.
2.2 Solvency
1REGN has an Altman-Z score of 6.56. This indicates that 1REGN is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 6.56, 1REGN belongs to the top of the industry, outperforming 88.89% of the companies in the same industry.
1REGN has a debt to FCF ratio of 0.76. This is a very positive value and a sign of high solvency as it would only need 0.76 years to pay back of all of its debts.
The Debt to FCF ratio of 1REGN (0.76) is better than 97.22% of its industry peers.
A Debt/Equity ratio of 0.09 indicates that 1REGN is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.09, 1REGN is in the better half of the industry, outperforming 69.44% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 0.76 | ||
| Altman-Z | 6.56 |
ROIC/WACC0.94
WACC9.91%
2.3 Liquidity
1REGN has a Current Ratio of 4.73. This indicates that 1REGN is financially healthy and has no problem in meeting its short term obligations.
1REGN's Current ratio of 4.73 is fine compared to the rest of the industry. 1REGN outperforms 79.17% of its industry peers.
1REGN has a Quick Ratio of 3.95. This indicates that 1REGN is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 3.95, 1REGN is doing good in the industry, outperforming 76.39% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.73 | ||
| Quick Ratio | 3.95 |
3. Growth
3.1 Past
1REGN shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 4.25%.
Measured over the past years, 1REGN shows a quite strong growth in Earnings Per Share. The EPS has been growing by 13.12% on average per year.
1REGN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 8.27%.
Measured over the past years, 1REGN shows a quite strong growth in Revenue. The Revenue has been growing by 12.55% on average per year.
EPS 1Y (TTM)4.25%
EPS 3Y-13.85%
EPS 5Y13.12%
EPS Q2Q%1.77%
Revenue 1Y (TTM)8.27%
Revenue growth 3Y-4.04%
Revenue growth 5Y12.55%
Sales Q2Q%10.34%
3.2 Future
1REGN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.78% yearly.
Based on estimates for the next years, 1REGN will show a small growth in Revenue. The Revenue will grow by 6.85% on average per year.
EPS Next Y-4.81%
EPS Next 2Y1.61%
EPS Next 3Y7.04%
EPS Next 5Y9.78%
Revenue Next Year3.48%
Revenue Next 2Y4.93%
Revenue Next 3Y7.07%
Revenue Next 5Y6.85%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 11.72, the valuation of 1REGN can be described as very reasonable.
90.28% of the companies in the same industry are more expensive than 1REGN, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of 1REGN to the average of the S&P500 Index (24.95), we can say 1REGN is valued rather cheaply.
The Price/Forward Earnings ratio is 12.32, which indicates a correct valuation of 1REGN.
Compared to the rest of the industry, the Price/Forward Earnings ratio of 1REGN indicates a rather cheap valuation: 1REGN is cheaper than 90.28% of the companies listed in the same industry.
1REGN's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 20.99.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.72 | ||
| Fwd PE | 12.32 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, 1REGN is valued cheaper than 91.67% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, 1REGN is valued cheaper than 87.50% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 16.53 | ||
| EV/EBITDA | 6.43 |
4.3 Compensation for Growth
1REGN has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.89
EPS Next 2Y1.61%
EPS Next 3Y7.04%
5. Dividend
5.1 Amount
1REGN has a yearly dividend return of 0.52%, which is pretty low.
1REGN's Dividend Yield is rather good when compared to the industry average which is at 8.51. 1REGN pays more dividend than 91.67% of the companies in the same industry.
With a Dividend Yield of 0.52, 1REGN pays less dividend than the S&P500 average, which is at 2.41.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.52% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr YearsN/A
Div Non Decr YearsN/A
5.3 Sustainability
DPN/A
EPS Next 2Y1.61%
EPS Next 3Y7.04%
BIT:1REGN (5/9/2025, 7:00:00 PM)
481.5
-53.7 (-10.03%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners89.84%
Inst Owner ChangeN/A
Ins Owners1.55%
Ins Owner ChangeN/A
Market Cap52.64B
Analysts78.24
Price Target976.66 (102.84%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.52% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4.7%
Min EPS beat(2)4.48%
Max EPS beat(2)4.93%
EPS beat(4)3
Avg EPS beat(4)2.24%
Min EPS beat(4)-7.23%
Max EPS beat(4)6.79%
EPS beat(8)7
Avg EPS beat(8)3.6%
EPS beat(12)10
Avg EPS beat(12)5.42%
EPS beat(16)14
Avg EPS beat(16)10.65%
Revenue beat(2)0
Avg Revenue beat(2)-0.77%
Min Revenue beat(2)-0.91%
Max Revenue beat(2)-0.62%
Revenue beat(4)1
Avg Revenue beat(4)-0.71%
Min Revenue beat(4)-4.23%
Max Revenue beat(4)2.93%
Revenue beat(8)5
Avg Revenue beat(8)0.95%
Revenue beat(12)9
Avg Revenue beat(12)1.83%
Revenue beat(16)12
Avg Revenue beat(16)4.72%
PT rev (1m)-6.4%
PT rev (3m)-11.72%
EPS NQ rev (1m)-12.86%
EPS NQ rev (3m)-13.96%
EPS NY rev (1m)-5.72%
EPS NY rev (3m)-5.8%
Revenue NQ rev (1m)-4.13%
Revenue NQ rev (3m)-2.22%
Revenue NY rev (1m)-0.39%
Revenue NY rev (3m)-0.55%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.72 | ||
| Fwd PE | 12.32 | ||
| P/S | 4.12 | ||
| P/FCF | 16.53 | ||
| P/OCF | 13.23 | ||
| P/B | 1.99 | ||
| P/tB | 2.07 | ||
| EV/EBITDA | 6.43 |
EPS(TTM)41.07
EY8.53%
EPS(NY)39.1
Fwd EY8.12%
FCF(TTM)29.13
FCFY6.05%
OCF(TTM)36.39
OCFY7.56%
SpS116.91
BVpS241.64
TBVpS232.19
PEG (NY)N/A
PEG (5Y)0.89
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.69% | ||
| ROE | 15.03% | ||
| ROCE | 12.47% | ||
| ROIC | 9.36% | ||
| ROICexc | 33.73% | ||
| ROICexgc | 38.44% | ||
| OM | 29.7% | ||
| PM (TTM) | 31.07% | ||
| GM | 87.01% | ||
| FCFM | 24.92% |
ROA(3y)12.83%
ROA(5y)18.14%
ROE(3y)16.47%
ROE(5y)24.86%
ROIC(3y)11.56%
ROIC(5y)16.89%
ROICexc(3y)38.5%
ROICexc(5y)36.52%
ROICexgc(3y)45.41%
ROICexgc(5y)40.67%
ROCE(3y)15.42%
ROCE(5y)22.52%
ROICexcg growth 3Y-3.25%
ROICexcg growth 5Y17.1%
ROICexc growth 3Y-7.38%
ROICexc growth 5Y14.08%
OM growth 3Y-18.89%
OM growth 5Y1.11%
PM growth 3Y-14.8%
PM growth 5Y2.92%
GM growth 3Y0.85%
GM growth 5Y-0.68%
F-Score6
Asset Turnover0.38
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 0.76 | ||
| Debt/EBITDA | 0.58 | ||
| Cap/Depr | 182.56% | ||
| Cap/Sales | 6.21% | ||
| Interest Coverage | 80.19 | ||
| Cash Conversion | 94.04% | ||
| Profit Quality | 80.2% | ||
| Current Ratio | 4.73 | ||
| Quick Ratio | 3.95 | ||
| Altman-Z | 6.56 |
F-Score6
WACC9.91%
ROIC/WACC0.94
Cap/Depr(3y)292.07%
Cap/Depr(5y)265.92%
Cap/Sales(3y)8.85%
Cap/Sales(5y)7.44%
Profit Quality(3y)83.77%
Profit Quality(5y)77.84%
High Growth Momentum
Growth
EPS 1Y (TTM)4.25%
EPS 3Y-13.85%
EPS 5Y13.12%
EPS Q2Q%1.77%
EPS Next Y-4.81%
EPS Next 2Y1.61%
EPS Next 3Y7.04%
EPS Next 5Y9.78%
Revenue 1Y (TTM)8.27%
Revenue growth 3Y-4.04%
Revenue growth 5Y12.55%
Sales Q2Q%10.34%
Revenue Next Year3.48%
Revenue Next 2Y4.93%
Revenue Next 3Y7.07%
Revenue Next 5Y6.85%
EBIT growth 1Y-2.71%
EBIT growth 3Y-22.17%
EBIT growth 5Y13.8%
EBIT Next Year0.3%
EBIT Next 3Y11.92%
EBIT Next 5Y8.61%
FCF growth 1Y-3.51%
FCF growth 3Y-18.47%
FCF growth 5Y12.09%
OCF growth 1Y-3.78%
OCF growth 3Y-14.54%
OCF growth 5Y12.71%